Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the launch of its XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a product designed to enhance artificial intelligence (AI)-powered high-throughput screening for antibody drug discovery. The kit leverages advanced cell-free protein synthesis technology to produce target proteins and antibodies in vitro, bypassing the limitations of traditional cell-based expression systems.
According to the company, the XPressMAX™ kit is based on an E. coli lysate and is fully supplemented with essential transcription and translation components, enabling direct protein synthesis from plasmid or PCR templates. It is specifically optimized for antibody drug discovery, supporting the rapid expression and validation of VHH, scFv, Fab, and miniproteins. The kit facilitates a high-throughput cell-free expression platform that can validate over 2,000 scFv/VHH molecules in 3-4 weeks, matching the rapid iteration cycles of AI.
Key highlights of the XPressMAX™ kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding without additional enhancers, ensuring native folding and bioactivity. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., stated: "Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality."
Dr. Jie Zhang, Sino Biological’s General Manager, added: "AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours." Researchers can visit www.sinobiological.com to explore more about XPressMAX™ or request a free sample via this link.
Sino Biological is an international reagent supplier and CRO service provider specializing in recombinant protein production and antibody development. With the US-based Center for Bioprocessing (C4B) in Houston and SignalChem Biotech in Canada, the company delivers tailored, localized solutions to researchers in over 90 countries. For more details on the cell-free protein synthesis system, visit the product page or the cell-free solutions page.
